Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1420-9071
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited ; volume:79 ; number:7 ; day:2 ; month:7 ; year:2022 ; pages:1-27 ; date:7.2022
Cellular and molecular life sciences ; 79, Heft 7 (2.7.2022), 1-27, 7.2022
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00018-022-04430-y
- URN
-
urn:nbn:de:101:1-2022101919485143933405
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hall, Daniella C. N.
- Benndorf, Ralf
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mutated hilltop inflation revisited
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin
PIK3CA is recurrently mutated in canine mammary tumors, similarly to in human mammary neoplasia
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma
XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis
Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example
Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway
Carcinogenesis of PIK3CA
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
Aspirin Days (Aspirin days : )
Mutated hilltop inflation revisited
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin
PIK3CA is recurrently mutated in canine mammary tumors, similarly to in human mammary neoplasia
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma
XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis
Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example
Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway
Carcinogenesis of PIK3CA
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
Aspirin Days (Aspirin days : )
Mutated hilltop inflation revisited
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin
PIK3CA is recurrently mutated in canine mammary tumors, similarly to in human mammary neoplasia
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma
XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis
Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example
Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway
Carcinogenesis of PIK3CA
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer